分子乳腺成像阴性结果的临床价值:初步概念验证
本研究回顾性纳入338例女性381个低 suspicion 病灶,计算分子乳腺成像(MBI)的阴性预测值和假阴性率。MBI阴性预测值为99.7%(95%CI:99.1%,100%),假阴性率为2.7%(95%CI:0%,7.9%),插入MBI使活检数量减少67.5%。作者认为阴性MBI结果的临床价值概念可能有效,但需进一步验证。
要点
- MBI对低 suspicion 病灶的阴性预测值达99.7%,阴性结果可高度排除乳腺癌。
- MBI假阴性率仅2.7%,但基于单例假阴性,置信区间宽(0%–7.9%)。
- 插入MBI可使活检数量减少67.5%,提示其可能减少不必要的活检。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To calculate the negative predictive value (NPV) and false-negative rate (FNR) of molecular breast imaging (MBI) performed in patients who had low-suspicion index findings on mammograms and US images.
MATERIALS AND METHODS: This retrospective study included patients who had undergone MBI between January 2015 and July 2017, who had index findings on screening mammograms and/or US images, and for whom either histopathologic results or a minimum of 1-year imaging follow-up results were available. A drawn dose of 8 mCi (296 MBq) of technetium 99m sestamibi was administered to all patients for MBI. The NPV and FNR of MBI was calculated for the cohort of 381 findings among 338 women (median age, 56 years; age range, 28-89 years) included in this study.
RESULTS: Overall, 292 of the 381 (76.6%) MBI results were interpreted as negative. Of the 292, 27 patients underwent subsequent biopsies, results of which were negative for cancer; one patient underwent biopsy, and the result was positive for cancer; and 264 patients had true-negative findings based on follow-up imaging for a minimum of 1 year. Of the 89 MBI acquisitions interpreted as positive, there were 36 cancers. The NPV was calculated to be 99.7% (291 of 292, 95% confidence interval [CI]: 99.1%, 100%), and the FNR was 2.7% (one of 37, 95% CI: 0%, 7.9%). Interposing MBI reduced the number of biopsies by 67.5%.
CONCLUSION: The concept of the clinical utility of a negative MBI result may be valid but requires further testing.Keywords: Breast, Molecular Imaging-Cancer© RSNA, 2020.
引用
- Jain R, Katz DR, Kapoor AD, et al. The Clinical Utility of a Negative Result at Molecular Breast Imaging: Initial Proof of Concept. Radiol Imaging Cancer. 2020. PMID: 33778735. doi:10.1148/rycan.2020190096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。